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intestinal Dysbiosis is associated 
with altered short-chain Fatty acids
and serum-Free Fatty acids in 
systemic lupus erythematosus
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Metabolic impairments are a frequent hallmark of systemic lupus erythematosus (SLE). 
Increased serum levels of free fatty acids (FFA) are commonly found in these patients, 
although the underlying causes remain elusive. Recently, it has been suggested that 
factors other than inflammation or clinical features may be involved. The gut micro-
biota is known to influence the host metabolism, the production of short-chain fatty 
acids (SCFA) playing a potential role. Taking into account that lupus patients exhibit 
an intestinal dysbiosis, we wondered whether altered FFA levels may be associated 
with the intestinal microbial composition in lupus patients. To this aim, total and specific 
serum FFA levels, fecal SCFA levels, and gut microbiota composition were determined 
in 21 SLE patients and 25 healthy individuals. The Firmicutes to Bacteroidetes (F/B) 
ratio was strongly associated with serum FFA levels in healthy controls (HC), even after 
controlling for confounders. However, this association was not found in lupus patients, 
where a decreased F/B ratio and increased FFA serum levels were noted. An altered 
production of SCFA was related to the intestinal dysbiosis in lupus, while SCFA levels 
paralleled those of serum FFA in HC. Although a different serum FFA profile was not 
found in SLE, specific FFA showed distinct patterns on a principal component analysis. 
Immunomodulatory omega-3 FFA were positively correlated to the F/B ratio in HC, but 
not in SLE. Furthermore, divergent associations were observed for pro- and anti-in-
flammatory FFA with endothelial activation biomarkers in lupus patients. Overall, these 
findings support a link between the gut microbial ecology and the host metabolism in 
the pathological framework of SLE. A potential link between intestinal dysbiosis and 
surrogate markers of endothelial activation in lupus patients is supported, FFA species 
having a pivotal role.
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inTrODUcTiOn
Epidemiological studies have consistently shown an increase in the prevalence and severity of a 
number of metabolic disorders in patients with systemic lupus erythematosus (SLE) compared to 
the general population (1–3). Among them, metabolic syndrome, disturbed glucose metabolism, or 
altered lipid metabolism are the most relevant. These disorders are related to an increased risk of 
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cardiovascular disease (CVD) development, the most important 
cause of mortality in SLE (4, 5), thus highlighting the clinical 
relevance of the metabolic alterations in SLE.
Immune dysregulation and chronic inflammation are known 
to promote endothelial dysfunction in SLE (6, 7). Increased levels 
of pro-inflammatory cytokines [such as tumor necrosis factor 
alpha (TNFα), interleukin-8 (IL-8), and monocyte chemoat-
tractant protein-1 (MCP-1)], adipokines, and autoantibodies 
are associated with the progression of endothelial dysfunction 
toward atherosclerosis development (6). At the local level, these 
mediators can impair the balance between endothelial repair 
and damage, whereas a number of systemic effects can be also 
triggered, including a shift to a pro-oxidant status (8) and altered 
lipid metabolism. In this scenario, although the underlying 
mechanisms are not totally understood, the relationship between 
systemic inflammation, metabolic disorders, and CVD may be 
explained, at least in part, by the free fatty acids (FFA) (9). FFA 
are fatty acid molecules released from adipocytes and several 
cell types upon lipolysis (10). Increased FFA levels in serum 
have been described in several metabolic disorders. Moreover, 
elevated serum FFA have also been found in immune-mediated 
diseases, such as SLE or rheumatoid arthritis, although striking 
differences were noted between both conditions (11). Rather than 
inflammatory or clinical parameters, the body mass index (BMI) 
was found to be the main predictor of FFA serum levels in lupus 
(11). However, these clinical studies did not allow the elucidation 
of the exact mediators and mechanisms involved.
Obesity is the result of an imbalance between energy intake 
and expenditure, which results in an excess of fat accumulation. 
However, several epidemiological studies have identified people 
with low BMI exhibiting markers of metabolic dysfunction (12, 
13). Similarly, healthy metabolic profiles are found in a subset of 
obese subjects (14, 15), hence suggesting that metabolic dysfunc-
tion (that is, impaired fatty acid mobilization) rather than adipos-
ity should be considered as the underlying cause. Therefore, it is 
feasible that factors related to energy intake and expenditure may 
underlie altered FFA levels and thus, metabolic disorders.
A mounting body of evidence shows that the gut microbiota 
can influence the host metabolism as well as the energy harvest 
and storage (16–18). Actually, the gut microbiota is seen by 
some authors as a separate endocrine organ involved, through a 
molecular cross talk with the host, in the maintenance of energy 
homeostasis and fat deposition (19). Currently, extensive 
research efforts have been focused on deciphering the basis of 
the cross talk between the microbiota and the host metabo-
lism in the development and progression of host diseases and 
have revealed the relevance of the intestinal microbiota–host 
metabolism axis mediated by different bacterial and host 
metabolites (20, 21). Thus, it may be speculated that changes in 
the intestinal microbial ecology could disrupt this homeostatic 
cross talk and precipitate the development of pathological 
outcomes in the host.
Recently, we have reported that SLE patients exhibit an 
altered intestinal composition compared to healthy subjects, 
mainly characterized by a decreased abundance of members 
of the Firmicutes phylum and an overrepresentation of those 
of Bacteroidetes (22). However, the clinical impact of this 
SLE-associated intestinal dysbiosis remains to be elucidated. 
Taking into account the former assumptions, we hypothesized 
that altered gut microbiota composition in SLE may underlie 
increased FFA serum levels. Accordingly, the main aims of 
the present report were (i) to analyze the potential association 
between the microbiota composition and FFA serum levels, 
(ii) to elucidate whether microbial metabolites can have a role 
in this interaction, (iii) to evaluate whether a different profile 
of FFA can be found in lupus patients, and (iv) to study the 
associations of these parameters with clinically relevant serum 
biomarkers.
MaTerials anD MeThODs
ethical approval
Ethical approval for this study was obtained from the Institutional 
Review Board (Comité de Ética de Investigación Clínica del 
Principado de Asturias) in compliance with the Declaration 
of Helsinki. All participants were informed and gave a signed 
informed consent prior their inclusion in the study.
Patients and controls
Our study involved 21 SLE patients, all fulfilling classification 
criteria for SLE. According to the 1982 revised criteria from the 
American College of Rheumatology, a definitive SLE diagnosis 
can be established when a patient exhibit at least 4 out of the 11 
SLE criteria (malar rash, discoid lesions, photosensitivity, oral 
ulcers, arthritis, serositis, renal disorders, neurological disorder, 
cytopenia, raised anti-DNA titers, and positivity to antinuclear 
antibodies) (23). A complete clinical examination, including 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 
calculation and anti-dsDNA autoantibodies assessment, was 
performed at the time of sampling. All patients were in remis-
sion (SLEDAI <8) at the sampling time. Information on clinical 
features along the disease course as well as the therapies received 
during the last 6 months was obtained from their clinical records. 
A group of 25 age- [median 43.50 (range 23.00–63.00) years] and 
gender-matched (23 females) healthy individuals recruited from 
the general population was included as the healthy controls (HC). 
Patients and controls did not differ in age (p = 0.293) and gender 
distribution (p =  0.495). Exclusion criteria were the history of 
recent infections, diagnosis of metabolic diseases, or the use of 
antibiotics, glucocorticoids, or monoclonal antibodies in the 
previous 6 months.
Upon acceptance of the individuals to participate in the study, 
a strict overnight fast (more than 8 h) blood sample was obtained 
in tubes without anticoagulant. Serum was collected, divided into 
aliquots, and samples were stored at −80°C until experimental 
procedures were performed. Additionally, basic serum blood 
lipid analyses were carried out on fresh samples at the time of 
sampling, by standardized procedures.
Quantification of Total FFa serum levels
Total FFA serum levels were analyzed by a colorimetric enzymatic 
assay using a commercial kit (NEFA kit half-microtest, Roche Life 
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Sciences, Penzberg, Germany) following the instructions from 
the manufacturer. Final absorbance was measured at 546 nm, and 
the detection limit was 0.2 mM.
assessment of serum FFa Profiles
Individual FFA were analyzed in serum samples following a 
methyl-tert-butylether-based extraction protocol (MTBE) as 
previously described (24), with minor modifications. Briefly, 
serum samples (100 µl) were spiked with 5 µl of internal standard 
(600 ppm heptadecanoic acid). Proteins were precipitated by the 
addition of 200 µl methanol chromasolv grade (Sigma Aldrich, 
MO, USA). Organic phases were obtained by the addition of 
1,200 µl MTBE chromasolv grade (Sigma) followed by an incu-
bation in an ultrasound water bath at 15°C for 30 min. Finally, 
organic phases were isolated by centrifugation at 5,000  rpm 
(7  min, 15°C) after the addition of 200  µl milliQ water. The 
extraction protocol was repeated once with 100 µl MetOH, 500 µl 
MTBE, and 100  µl milliQ H2O. Lipid extracts were dried in a 
miVac centrifugal evaporator (Genevac Ltd., UK) and redissolved 
in 100 µl of water:acetonitrile (38:62).
The analyses of fatty acids in the samples were performed 
in a Dionex Ultimate 3000 HPLC system (Thermo Scientific, 
Bremen, Germany) equipped with a column Zorbax Eclipse 
Plus C18 (50 mm ×  2.1 mm, 1.8 μm). Mobile phases A and B 
were water and acetonitrile, respectively, both containing 0.1% of 
formic acid. Fatty acids were separated in an injection volume of 
2 µl by a gradient program as follows: 62% B (held for 4.5 min) 
followed by a linear increase up to 100% B in 10 min (held for 
1 min). The column temperature was set at 45°C. Mass detection 
was carried out in a Bruker Impact II q-ToF mass spectrometer 
with electrospray ionization, operating in the negative mode. The 
settings of the mass spectrometer were as follows: spray voltage 
4.5 kV; drying gas flow 12 l/min; drying gas temperature 250°C; 
and nebulizer pressure 44 psi.
For quantification, calibration curves for each compound 
were prepared by dissolution of the pure standards in methanol 
to adequately encompass the expected concentration of the 
analytes in the samples. The calibration ranges were as follows: 
0.4–12.5 µg/ml for EPA and γ-linolenic; 1.2–37.5 µg/ml for DHA 
and linolenic; 2.3–75 µg/ml for AA and palmitoleic; 3.9–125 µg/ml 
for linoleic; and 7.8–250  µg/ml for oleic, palmitic, and stearic 
acids. A good linearity was observed in all cases (r2 >  0.994). 
Heptadecanoic acid was used as internal standard to account for 
potential biases during the extraction protocol.
analysis of Fecal Microbiota
Fecal sample collection and metagenomic analyses of fecal 
microbiota were performed as previously reported (22). 
Briefly, fresh fecal material was processed within 3  h from 
collection and immediately homogenized and stored at −80°C. 
Fecal DNA was extracted with a QIAampDNA stool minikit 
(Qiagen, Strasse, Germany). Then, 16S rRNA gene sequences 
were amplified, and 16S rRNA and gene-based amplicons were 
sequenced by an Ion Torrent PGM sequencing platform as 
described elsewhere (22).
analysis of short-chain Fatty  
acids (scFa) in Fecal samples
Analysis of SCFA (acetate, propionate, and butyrate) was per-
formed by gas chromatography. Briefly, 1 g of fecal samples was 
diluted 1:10 in sterile PBS and homogenized in a LabBlender 400 
stomacher (Seward Medical, London, UK) at full speed for 4 min. 
Then, supernatants were obtained by centrifugation (10.000 × g, 
30 min, 4°C), filtered through 0.2-µm filters, mixed with 1:10 of 
ethyl butyric acid (2 mg/ml) as an internal standard, and stored 
at −80°C until analysis.
A gas chromatograph 6890N (Agilent Technologies Inc., Palo 
Alto, CA, USA) connected to a mass spectrometry (MS) 5973N 
detector (Agilent Technologies) and to a flame ionization detector 
was used for identification and quantification of SCFA. Data were 
collected using the Enhanced ChemStation G1701DA software 
(Agilent). Samples (1  µl) were injected into the gas chromato-
graph equipped with an HP-Innowax capillary column (60-m 
length by 0.25-mm internal diameter, with a 0.25-µm film thick-
ness; Agilent) using He as a gas carrier (flow rate of 1.5 ml/min). 
The temperature of the injector was kept at 220°C, and the split 
ratio was 50:1. Chromatographic conditions were as follows: 
initial oven temperature of 120°C, 5°C/min up to 180°C, 1 min at 
180°C, and a ramp of 20°C/min up to 220°C to clean the column. 
In the MS detector, the electron impact energy was set at 70 eV. 
The data collected were in the range of 25 to 250 atomic mass 
units (at 3.25 scans/s).
SCFA were identified by comparison of their mass spectra 
with those held in the HP-Wiley 138 library (Agilent) and 
by comparison of their retention times with those of the 
corresponding standards (Sigma Aldrich, St. Louis, MO, 
USA). The peaks were quantified as relative abundances with 
respect to the internal standard. The concentration (in mil-
limolar) of each SCFA was calculated using the linear regres-
sion equations (R2  ≥  0.99) from the corresponding standard 
curves.
analysis of serum Biomarkers
Soluble Biomarkers
Serum levels of vascular endothelial growth factor (VEGF), 
granulocyte monocyte colony-stimulating factor (GM-CSF), and 
IL-8 were analyzed by Cytometric Bead Arrays (BD Biosciences, 
NJ, USA) using a BD FACS Canto II and FACS Diva software. 
Detection limits were 4.5, 0.2, and 1.2 pg/ml, respectively.
Epidermal growth factor (EGF), TNFα, MCP-1, interferon 
gamma-inducible protein-10 (IP-10), and leptin serum levels 
were assessed by plate immunoassays using commercial kits by 
Peprotech (NJ, USA), following manufacturer’s instructions. 
Detection limits were 3.9, 3.9, 8, 3.9, and 24 pg/ml, respectively.
Malondialdehyde (MDA)
Malondialdehyde serum levels were determined by means 
of a colorimetric method using a commercial kit (LPO-596, 
Byoxytech, Oxis International, France). Final absorbance was 
read at 586 nm.
TaBle 2 | analysis of the correlation between serum FFa levels and 
demographical and nutritional features in healthy controls (hc) and 
systemic lupus erythematous (sle) patients.
hc sle
Age r = −0.260 r = −0.179
p = 0.231 p = 0.451
Total cholesterol r = −0.108 r = −0.203
p = 0.625 p = 0.390
HDL-cholesterol r = 0.220 r = 0.114
p = 0.313 p = 0.633
LDL-cholesterol r = −0.028 r = −0.248
p = 0.898 p = 0.291
Triglycerides r = −0.224 r = −0.078
p = 0.305 p = 0.743
BMI r = 0.247 r = 0.214
p = 0.268 p = 0.366
Total energy r = 0.082 r = −0.212
p = 0.710 p = 0.369
Carbohydrates r = −0.107 r = −0.311
p = 0.628 p = 0.182
Lipids r = −0.048 r = −0.220
p = 0.826 p = 0.352
Proteins r = 0.010 r = −0.005
p = 0.964 p = 0.985
Fiber r = 0.125 r = −0.394
p = 0.568 p = 0.086
Correlations were assessed by Spearman ranks tests  (r coefficient and p-value is 
indicated for each parameter).
TaBle 1 | serum-free fatty acids (FFa) levels, nutritional parameters 
and blood lipid profiles of the healthy controls (hc) and systemic lupus 
erythematosus (sle) patients recruited in this study.
hc (n = 25) sle (n = 21) p
FFa assessment
Total FFA (mM) 0.27 (0.17) 0.41 (0.26) 0.045
Blood lipid analyses
Total cholesterol (mg/dl) 191.50 (49.00) 200.00 (61.25) 0.732
HDL-cholesterol (mg/dl) 62.00 (14.75) 62.00 (24.00) 0.740
LDL-cholesterol (mg/dl) 114.50 (50.00) 111.50 (57.50) 0.530
Triglycerides (mg/dl) 68.50 (54.25) 71.55 (45.25) 0.715
nutritional parameters
Total energy (kcal/day) 1,888.88 (226.53) 2,186.11 (208.16) 0.069
Carbohydrates (g/day) 202.50 (51.60) 205.46 (102.95) 0.944
Lipids (g/day) 78.13 (29.32) 79.42 (63.57) 0.789
Proteins (g/day) 96.98 (15.81) 102.60 (34.30) 0.782
Fiber (g/day) 24.68 (6.17) 26.47 (6.57) 0.609
Body mass index (kg/m2) 24.96 (4.47) 24.58 (7.78) 0.715
Variables are represented as median (interquartile range) or n (%) unless otherwise 
stated. Differences in demographical and blood lipid variables were assessed by 
Mann–Withney U tests, whereas differences in daily intakes were analyzed by 
multivariate analyses adjusted for confounders. Energy was adjusted by gender and 
age, whereas the rest of the nutrients were adjusted by gender, age, and energy.
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anthropometric Measures
Height was measured using a stadiometer with an accuracy of 
±1 mm (Año-Sayol, Barcelona, Spain). The subjects stood bare-
foot, in an upright position and with the head positioned in the 
Frankfort horizontal plane. Weight was measured on a scale with 
an accuracy of ±100 g (Seca, Hamburg, Germany).
nutritional assessments
Dietary intakes were assessed by means of an annual semiquan-
titative validated food frequency questionnaire including 160 
items (25). During an interview by trained dietitians, subjects 
were asked, item by item, whether they usually ate each food 
and, if so, how much they usually ate. For this purpose, three 
different serving sizes of each cooked food were presented in 
pictures to the participants so that they could choose from up 
to seven serving sizes (from “less than the small one” to “more 
than the large one”). For some of the foods consumed, amounts 
were recorded in household units, by volume, or by measuring 
with a ruler. Information on the cooking practices, number and 
amount of ingredients used in each recipe, and other relevant 
information for the study was collected. Methodological issues 
concerning dietary assessment have been detailed elsewhere 
(25). The consumption of foods was converted into energy intake 
(kilocalories per day), macronutrients (carbohydrates, lipids, and 
proteins, grams per day), and total fiber (grams per day) using 
the nutrient food composition tables developed by the Centro de 
Enseñanza Superior de Nutrición Humana y Dietética (CESNID) 
(26). CESNID, a foundation, involves different institutions, uni-
versities, and companies related to the food and nutrition area, 
and its food composition databases are supported by the Spanish 
Association of Nutrition and Dietetics.
statistical analyses
Continuous variables were expressed as median (interquartile 
range) or mean ± SD. Mann–Whitney U, Student’s t or Kruskal–
Wallis tests were performed to assess statistical differences. 
Correlations were analyzed by Spearman’s rank or Pearson tests, 
depending on the distribution of the data. Categorical variables 
were summarized as n (%), and differences were analyzed by χ2 
tests. A principal component analysis (PCA) was performed to 
avoid potential bias due to collinearity. The adequacy of the data was 
studied by Kaiser–Meyer–Olkin test and Bartlett test of sphericity. 
The number of components retained was based on eigenvalues 
(>1), and loadings greater than 0.5 were used to identify the vari-
ables comprising each component. Unsupervised cluster analysis 
was performed based on squared Euclidean distances, and Ward’s 
Minimum Variance method was used to identify the clusters. 
Heatmaps were generated under R package heatmap.2. SPSS 21.0, 
R 3.0.3, and GraphPad Prism 5.0 for Windows were used.
resUlTs
Total FFa serum levels in sle Patients: 
association with intestinal Dysbiosis
The concentration of total FFA was measured in serum samples 
from 21 SLE patients and 25 matched HC (Table 1). SLE patients 
exhibited higher FFA serum levels (Table 1). Differences between 
groups in the levels of FFA remained significant after adjusting 
for age and gender (p = 0.024). Moreover, no associations were 
found with demographical parameters, cholesterol and triglycer-
ides levels, and dietary intakes (Table 2). Furthermore, FFA were 
neither related to clinical manifestations (Table 3) (all p > 0.050) 
nor disease activity (r = −0.349, p = 0.169), duration (r = −0.005, 
TaBle 3 | Demographical and clinical parameters of the systemic lupus 
erythematosus (sle) patients.
sle (n = 21)
Age, (years), mean (range) 48.35 (27.00–70.00)
Gender, (f/m) 21/0
Age at diagnosis, (years) 33.00 (14.50)
Disease duration, (years), median (range) 7.00 (2.00–24.00)
SLEDAI score 4.00 (3.25)
clinical manifestations, n(%)
Malar rash 12 (57.1)
Photosensitivity 16 (76.2)
Discoid lesions 6 (28.6)
Arthritis 10 (47.6)
Oral ulcers 10 (47.6)
Serositis 4 (19.0)
Renal disorder 3 (14.3)
Neurological disorder 0 (0.0)
Cytopenia 11 (52.4)
autoantibodies, n(%)
ANAs 21 (100)
Anti-dsDNA titer, (U/ml), mean ± SD 25.30 ± 33.89
Anti-SSa 11 (52.4)
Anti-SSb 2 (9.5)
Anti-Sm 2 (9.5)
Anti-RNP 1 (4.8)
Treatments, n (%)
None or NSAIDs 3 (14.2)
Antimalarials 18 (85.7)
Variables are represented as median (interquartile range) or n(%), unless otherwise 
stated.
TaBle 4 | association between serum-free fatty acids (FFa) levels and 
gut microbiota composition in healthy controls (hc) and systemic lupus 
erythematosus patients (sle).
hc sle)
Actinobacteria r = 0.075 r = −0.415
p = 0.733 p = 0.069
Bacteroidetes r = 0.721 r = 0.311
p < 0.0001 p = 0.182
Firmicutes r = −0.574 r = −0.117
p = 0.007 p = 0.622
Cyanobacteria r = −0.120 r = −0.401
p = 0.539 p = 0.080
Euryarchaeota r = −0.213 r = −0.063
p = 0.328 p = −0.792
Fusobacteria r = −0.052 r = 0.139
p = 0.812 p = 0.560
Lentisphaerae r = 0.272 r = 0.019
p = 0.210 p = 0.937
Proteobacteria r = −0.158 r = 0.230
p = 0.471 p = 0.329
Tenericutes r = −0.105 r = −0.220
p = 0.634 p = 0.227
TM7 r = 0.015 r = 0.018
p = 0.945 p = 0.939
Verrucomicrobia r = −0.325 r = 0.209
p = 0.130 p = 0.376
Synergistetes r = −0.211 r = −0.104
p = 0.334 p = 0.661
The associations between serum FFA levels and the abundance of microbial groups 
at the level of phyla in HC and SLE patients were analyzed by Spearman ranks tests 
(r coefficient and p-value is indicated for each parameter). Statistical analyses with a 
p-value below 0.050 are highlighted in bold.
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p = 0.982), or anti-dsDNA levels (r = −0.350, p = 0.130) in SLE. 
Therefore, parameters other than those indicated may explain the 
altered serum FFA levels registered in SLE.
Then, we wondered whether gut microbial composition may 
account for the increased FFA serum levels in SLE. To this aim, 
the associations between FFA levels and the main intestinal 
microbial groups analyzed by a metagenomic approach as 
already described (22) were assessed. As previously reported, 
diminished Firmicutes to Bacteroidetes (F/B) ratio character-
ized the intestinal dysbiosis found in SLE compared to healthy 
subjects [1.94 (1.51) vs 4.27 (5.93), p  <  0.001] (22). Among 
the phyla analyzed (Actinobacteria, Bacteroidetes, Firmicutes, 
Cyanobacteria, Euryarchaeota, Fusobacteria, Lentisphaerae, 
Proteobacteria, Tenericutes, TM7, Verrucomicrobia, and 
Synergistetes), FFA levels displayed opposite correlations with 
the Firmicutes and Bacteroidetes groups in HC, but not in lupus 
patients (Table  4). Consequently, a negative association with 
the F/B ratio was observed in HC, but not in SLE (Figure  1). 
Moreover, this association remained significant after adjusting for 
potential confounders (Table 5). Therefore, F/B ratio was found 
to be the main predictor of FFA serum levels in HC, whereas this 
effect was not seen in lupus patients, hallmarked by a decreased 
F/B ratio and elevated FFA levels.
Since some heterogeneity within groups in the FFA levels was 
observed and in order to gain more insight into the connections 
between gut microbiota and serum FFA, further analyses were 
performed. Focusing on the main microbial groups at the level 
of phyla, individuals were classified into groups by means of a 
cluster analysis. Interestingly, two main clusters were identified 
(thereafter referred to as clusters I and II) (Figure 2A), mainly 
differing in the F/B ratio (8.84 ± 5.53 vs 1.70 ± 0.76, respectively; 
p <  0.0001). Notably, a distinct distribution of individuals was 
observed, as HC were mainly found within the cluster I (14/25), 
whereas SLE patients were marginally present in this group (3/21, 
p = 0.004). On the one hand, this result highlights a shift in the 
microbiota composition in SLE patients compared to HC, hence 
supporting an association between a biased distribution of the 
intestinal microbial groups and elevated FFA serum levels. More 
importantly, when FFA levels were compared among HC and 
SLE subjects stratified by microbial clusters, it was noted that HC 
grouping within the cluster II exhibited similar FFA serum levels 
as SLE patients (Figure 2B), thus reinforcing the relevance of the 
microbiota composition on the FFA serum levels.
Overall, our findings disclose a strong association between 
FFA levels in serum and specific groups of the gut microbiota in 
healthy individuals, but not in lupus patients where a profound 
intestinal dysbiosis was registered.
scFa and FFa levels
Our results point to a relationship between the gut microbiota and 
the host metabolism at the systemic level, but the actual media-
tors are unclear. Since SCFA may affect the human metabolism 
TaBle 5 | Firmicutes/Bacteroidetes (F/B) ratio is the main predictor 
of FFa levels in healthy controls (hc) but not in systemic lupus 
erythematosus (sle) patients.
β B [95% ci] p
hc F/B ratio −0.636 −0.334 [−0.557, −0.111] 0.007
Age −0.354 −0.652 [−1.436, 0.132] 0.093
Gender 0.150 0.114 [−0.179, 0.407] 0.405
BMI −0.039 −0.002 [−0.022, 0.018] 0.832
CRP 0.191 0.133 [−0.170, 0.436] 0.352
Total energy −0.010 0.001 [−0.044, 0.042] 0.961
Lipids 0.276 0.003 [−0.004, 0.010] 0.315
Carbohydrates −0.372 −0.002 [−0.004, 0.001] 0.073
Proteins 0.092 0.001 [−0.005, 0.007] 0.690
Fiber −0.223 −0.007 [−0.020, 0.005] 0.239
sle F/B ratio −0.025 −0.014 [−0.332, 0.303] 0.923
Age −0.229 −0.336 [−1.315, 0.643] 0.466
BMI 0.415 0.012 [−0.008, 0.032] 0.205
CRP 0.186 0.072 [−0.191, 0.335] 0.558
Total energy −0.072 −0.007 [−0.045, 0.031] 0.687
Lipids −0.193 −0.001 [−0.005, 0.003] 0.698
Carbohydrates −0.265 −0.001 [−0.003, 0.002] 0.649
Proteins 0.369 0.002 [−0.002, 0.006] 0.308
Fiber −0.351 −0.006 [−0.019, 0.008] 0.365
The association between F/B ratio and FFA serum levels in HC was studied by multiple 
lineal regression analysis including demographical parameters and nutritional intakes 
as potential confounders. HC: R2 (model) = 0.762; SLE: R2 (model) = 0.426. Statistical 
analyses with a p-value below 0.050 are highlighted in bold.
FigUre 1 | serum-free fatty acids (FFa) levels and Firmicutes to 
Bacteroidetes (F/B) ratio. The association between serum FFA levels and 
the F/B ratio was analyzed by Spearman’s ranks correlation tests.
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and an altered gut microbiota composition leads to a dysregulated 
SCFA production, the associations between fecal SCFA levels and 
those of serum FFA were analyzed.
On the one hand, higher levels of all SCFA studied were 
observed in lupus patients compared to HC (Table 6). However, 
no differences were found between SLE and HC when relative 
proportions were compared (all p > 0.050). On the other hand, 
all SCFA exhibited a positive correlation with FFA serum levels 
in HC (Table 6).
Importantly, the F/B ratio was negatively correlated to the fecal 
levels of propionate and butyrate in HC but not in SLE patients 
(Figure  3). Notably, stronger associations were found in HC 
when only Bacteroidetes abundance was considered: propionate 
(r = 0.653, p < 0.001) and butyrate (r = 0.623, p = 0.002).
In order to gain further insight into the relevance of the intesti-
nal microbiota and the SCFA production and serum FFA levels, we 
performed additional analyses by stratifying subjects according 
to the clusters obtained from the microbiota analysis (Figure 2) 
instead of their clinical condition. Interestingly, a negative asso-
ciation between F/B ratio and fecal SCFA was found in cluster 
I (propionate: r = −0.621, p = 0.024 and butyrate: r = −0.654, 
p =  0.015), but not in those grouped in cluster II (propionate: 
r = −0.015, p = 0.940 and butyrate: r = 0.220, p = 0.271). Overall, 
this picture mirrors that of found for the HC vs SLE populations 
according to our previous findings and confirms a pivotal role 
of the intestinal microbiota in this scenario. However, SCFA and 
FFA levels did not remain associated after stratifying the whole 
population by the clusters, hence suggesting the involvement of 
additional factors, such as the clinical condition, to explain the 
connection between gut microbiota composition, SCFA, and 
serum FFA levels.
All these results highlight a role for the gut microbiota in 
the maintenance of serum FFA levels, SCFA having a potential 
role orchestrating this interaction. Additional factors, such as 
disease status, may also influence the outcome of the associa-
tions between gut microbiota composition and the interaction 
SCFA–FFA. Indeed, altered gut microbiota composition 
found in SLE patients was linked to an altered SCFA produc-
tion and increased FFA levels in serum, thus supporting this 
hypothesis.
FFa Profiling in sle Patients
Although elevated FFA levels were found in SLE, whether a global 
increase in all FFA species underlies this finding, or if some specific 
FFA were altered was not clear. To address this issue, a number 
of FFA species were measured, and the differences between SLE 
and HC were studied.
Overall, no striking differences were observed between 
patients and controls (Table 7). However, since some collinearity 
among FFA species existed, a PCA was carried out on the FFA 
species analyzed to avoid potential biases. PCA demonstrated 
a good adequacy of the data (KMO statistic =  0.781, Barlett 
sphericity test p = 10−44), and three components were identified 
(eigenvalues >1) explaining 77.53% of the total variance. Based 
on their loadings, PC1 (53.32% variance explained) retained 
γ-linolenic, palmitoleic, palmitic, oleic, linolenic, linoleic, and 
arachidonic acids, and PC2 (13.95% variance explained) mainly 
retained EPA and DHA. Finally, PC3 (10.26% variance explained) 
only retained stearic acid (Figure 4).
On the one hand, these results underlie the outstanding het-
erogeneity of FFA species, a clearly distinct pattern of grouping 
depending on their chemical structure (chain length or double-
bond position) not being found. Globally, saturated, monounsatu-
rated, and w6 fatty acids were grouped together within the PC1, 
whereas the most important anti-inflammatory w3 FFA did in the 
PC2. Stearic acid, of controversial immunological and metabolic 
role, was grouped in the third component. Hence, these findings 
support a functional, rather than structural, relationship of FFA.
FigUre 2 | cluster analysis revealed a link between gut microbiota composition and total free fatty acids (FFa) serum levels. (a) Heatmap plotting gut 
microbiota composition, based on the main phyla, in healthy controls (HC) and systemic lupus erythematosus (SLE) patients. Tiles are colored based on the 
abundance of each group, red and blue colors indicating low or high levels, respectively. Each row represents an individual, and the vertical colored bar at the left 
represents HC (dark red) or SLE patient (gray). Two clusters were identified and are highlighted at the right (clusters I and II). (B) Comparison of total FFA serum 
levels among groups after stratifying by disease status (HC or SLE) and microbiota clusters (I or II). Boxes represent median and interquartile range, whereas 
whiskers represent minimum and maximum values. Differences were assessed by Kruskal–Wallis test and Dunn–Bonferroni post hoc correction for multiple 
comparisons tests. *p < 0.050, **p < 0.010.
TaBle 6 | analysis of fecal short-chain fatty acids (scFa) levels and their 
correlation with serum-free fatty acids (FFa) levels in healthy controls 
(hc) and systemic lupus erythematosus (sle) patients.
hc sle p
scFa levels (mM)
Acetate 41.14 (12.30) 57.63 (19.63) 0.005
Propionate 11.96 (8.72) 20.61 (9.80) 0.003
Butyrate 7.78 (3.97) 10.50 (7.14) 0.075
scFa–FFa correlations
Acetate r = 0.770 r = 0.067
p < 0.001 p = 0.793
Propionate r = 0.790 r = 0.230
p < 0.001 p = 0.359
Butyrate r = 0.764 r = −0.066
p < 0.001 p = 0.795
The differences between fecal SCFA levels found in lupus patients and those in HC 
were analyzed by Mann–Withney U tests; whereas the correlation analyses were 
performed by Spearman rank’s tests. Variables are summarized as median (interquartile 
range). Statistical analyses with a p-value below 0.050 are highlighted in bold.
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On the other hand, no differences in the PCA scores were 
registered between SLE and HC groups (PC1: p =  0.169, PC2: 
p = 0.378, and PC3: p = 0.916), thus suggesting that SLE patients 
did not exhibit a different FFA profile compared to HC.
Finally, whether PCA scores could be related to gut microbiota 
composition was analyzed. Notably, F/B ratio was positively cor-
related with the PC2 score (Table 8) in HC but not in SLE, thereby 
suggesting a beneficial effect of gut microbiota composition on 
the serum FFA pool in healthy individuals. Again, when the phyla 
were independently studied, Bacteroidetes exhibited a stronger 
correlation with PC2 score (r = −0.433, p = 0.039) than that of 
Firmicutes (r =  0.411, p =  0.052) in HC individuals. Thus, gut 
microbiota seems to quantitatively and qualitatively impact the 
FFA serum pool.
FFa and serum Biomarkers  
in sle Patients
Since some associations between gut microbiota and specific FFA 
PCA scores were observed, we aimed to evaluate whether these 
TaBle 7 | specific free fatty acids (FFa) in healthy controls (hc) and 
systemic lupus erythematosus (sle) patients.
FFa (μg/ml) hc sle p
Palmitic (16:0) 32.76 (15.59) 30.35 (8.37) 0.982
Stearic (18:0) 28.51 (12.95) 29.12 (6.19) 0.873
Palmitoleic (16:1ω7) 1.93 (1.62) 2.67 (0.99) 0.351
Oleic (18:1ω9) 27.76 (20.61) 34.39 (17.77) 0.467
Linoleic (18:2ω6) 6.99 (6.47) 10.26 (7.35) 0.246
γ-Linoleic (18:3ω6) 0.08 (0.08) 0.10 (0.06) 0.785
AA (20:4ω6) 1.96 (1.68) 2.74 (1.74) 0.045
Linolenic (18:3ω3) 0.18 (0.17) 0.20 (0.16) 0.539
EPA (20:5ω3) 0.07 (0.15) 0.15 (0.17) 0.363
DHA (22:6ω3) 1.47 (1.46) 1.65 (1.76) 0.209
The differences in specific FFA serum levels between control and patients were 
assessed by Mann–Withney U tests. Variables are summarized as median (interquartile 
range). Statistical analyses with a p-value below 0.050 are highlighted in bold.
FigUre 3 | association between fecal short-chain fatty acids (scFa) levels and Firmicutes to Bacteroidetes ratio. Correlation analyses by Spearman’s 
ranks tests were performed in order to analyze the association between fecal SCFA levels and those of serum-free fatty acids in healthy controls (a) and systemic 
lupus erythematosus patients (B).
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parameters could be related to some relevant serum biomarkers 
in lupus. To this end, a panel of serum biomarkers of endothelial 
activation (VEGF, GM-CSF, EGF, IL-8, TNFα, MCP-1, IP-10, and 
leptin) and oxidative stress (MDA) were measured (Table 9).
First, the associations between these biomarkers and the gut 
microbiota composition were analyzed. Interestingly, the F/B 
ratio was negatively associated to leptin (r = −0.369, p = 0.006) 
and MCP-1 serum levels (r = −0.304, p = 0.025) in the whole 
group.
On the other hand, divergent associations were noted among 
FFA PCA scores and these biomarkers in SLE patients. Whereas 
PC1 was positively correlated with biomarkers of endothelial 
activation [VEGF (r  =  0.444, p  =  0.044), IL-8 (r  =  0.522, 
0.015), and EGF (r =  0.400, p =  0.070)], negative associations 
were observed for PC2 [EGF (r = −0.425, p =  0.055), MCP-1 
(r = −0.640, p =  0.002), IP-10 (r = −0.397, p =  0.075), TNFα 
(r = −0.410, p =  0.065), and MDA (r = −0.375, p =  0.057)]. 
Interestingly, negative associations were also found for PC3 
[VEGF (r = −0.534, p = 0.013) and IL-8 (r = −0.459, p = 0.036)]. 
No associations were observed in the HC.
All these findings seem to point to a link between gut microbi-
ota, FFA serum pool, and biomarkers of endothelial activation in 
lupus, thus emphasizing the systemic effect of the gut microbiota 
in this condition. Additionally, differences among FFA PCA are 
in line with their proposed functional diversity.
DiscUssiOn
Over the last decade, several studies have revealed a number 
of interactions between the gut microbiota and the host in 
homeostatic conditions. Accordingly, dysbiosis has been consist-
ently related to different pathological situations, from immune-
mediated to metabolic diseases (27–29). In this sense, we have 
recently reported the existence of an intestinal dysbiosis in SLE 
FigUre 4 | Principal component analysis (Pca) of specific free fatty acids (FFa) profiling. Biplot obtained in the PCA of specific FFA serum levels. PC1 and 
PC2 are represented in the horizontal and vertical axes, respectively. Arrows represent the vectors showing the associations among the raw variables entered in the 
analysis. Individuals are represented in colored dots: healthy controls (HC) (turquoise) and systemic lupus erythematosus (SLE) (red).
TaBle 8 | associations between Firmicutes to Bacteroidetes ratio and 
free fatty acids-principal component analysis scores in healthy controls 
(hc) and systemic lupus erythematosus (sle) patients.
hc sle
PC1 r = −0.246 r = 0.078
p = 0.257 p = 0.736
PC2 r = 0.437 r = 0.110
p = 0.037 p = 0.635
PC3 r = −0.075 r = 0.089
p = 0.734 p = 0.700
Correlations between these parameters were assessed by Pearson correlation tests. 
Statistical analyses with a p-value below 0.050 are highlighted in bold.
TaBle 9 | levels of serum biomarkers analyzed in healthy controls (hc) 
and systemic lupus erythematosus (sle) patients.
hc sle p
Vascular endothelial growth
factor [VEGF] (pg/ml)
83.38 (49.49) 70.73 (98.87) 0.326
Granulocyte monocyte 
colonystimulating factor 
[GM-CSF] (pg/ml)
0.35 (0.92) 0.35 (2.77) 0.424
Epidermal growth factor [EGF] 
(pg/ml)
114.29 (81.35) 65.57 (78.61) 0.019
Interleukin-8 [IL-8] (pg/ml) 14.69 (22.51) 27.85 (21.92) 0.016
Tumor necrosis factor alpha 
[TNFα] (pg/ml)
174.40 (309.4) 188.14 (292.92) 0.789
Monocyte chemoattractant
protein-1 [MCP-1] (pg/ml)
444.55 (481.45) 616.13 (402.07) 0.011
Interferon gamma-inducible
protein-10 [IP-10] (pg/ml)
98.82 (148.81) 167.67 (152.76) 0.019
Leptin (ng/ml) 7.73 (7.14) 14.16 (20.20) <0.001
Malondialdehyde [MDA] (μM) 2.78 (0.71) 2.90 (0.44) 0.658
The differences in serum levels between control and patients were assessed by  
Mann–Withney U tests. Variables are summarized as median (interquartile range). 
Statistical analyses with a p-value below 0.050 are highlighted in bold.
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(22). Additional studies from our group allowed us to associate the 
dysbiotic state with the dysregulated Treg/Th17 responses found 
in lupus patients (30). In the present report, we go a step further 
by addressing the study of the potential connections between the 
intestinal dysbiosis and the metabolic impairment in SLE, focus-
ing on the role of FFA. Thus, gut microbiota may not only be 
related to disease pathogenesis itself but also to some comorbidi-
ties frequently present in lupus patients. Since the origin of such 
alterations is ill-defined, these new findings allow us to gain some 
insight into this complex situation and may help to delineate 
new therapeutic targets. Actually, the experimental modulation 
of the gut microbiota has yielded promising results in other 
scenarios  (17). In fact, the lupus-like immune over-activation 
was partially reestablished in vitro by the supplementation with 
specific bacterial strains (30). Thus, our study warrants future 
research to assess whether this therapy may be also advisable to 
counteract the metabolic alterations in SLE patients.
Metabolic disorders, including metabolic syndrome, are 
common hallmarks of SLE and other related diseases (31–33). 
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However, the underlying causes of these traits are not well 
defined. The findings herein presented suggest that gut micro-
biota may play a role in this condition. This notion can explain 
why a wide range of diseases, with striking differences in their 
clinical presentations, are associated with similar comorbidities 
(such as metabolic alterations). Thus, it is feasible to think that 
similar patterns of intestinal dysbiosis may underlie this situation. 
This idea is supported by the altered F/B ratios that were reported 
in other diseases exhibiting increased serum FFA levels (34–36). 
The fact that this ratio is a continuum may explain the differences 
in prevalence and severity of metabolic complications among 
different conditions. However, it must be remarked that studies 
on the alterations in the F/B ratio have yielded contradictory 
results in different contexts, such as obesity (37–39). Schwiertz 
and colleagues have recently published a reduced F/B ratio in 
obese and overweighed individuals in a large study population 
(40). Similarly, the enrichment of Firmicutes in the intestinal 
ecosystem has been related to improved lipid absorption and 
homeostasis in animal models (41). It must be taken into account 
that differences in sequencing techniques, data analysis, and 
characteristics of the recruited populations may be an important 
source of discrepancy in this field. Thus, the associations of the 
microbiota with metabolic traits in different scenarios must be 
interpreted with caution, since direct comparison is not always 
possible. Additional studies focusing on the F/B ratio in non-
obese healthy population are warranted.
The association between the F/B ratio and the serum levels 
of FFA emphasizes the ability of the gut microbiota to promote 
systemic responses in the host. Moreover, it supports that gut 
microbiota can modulate the energy metabolism of the host (42). 
However, the identification of the actual mediators involved and 
the potential impact of this interaction in pathological conditions 
is currently lacking in the literature. Our findings in the present 
work point to the SCFA as potential orchestrators of the cross 
talk between gut microbiota and the host metabolism. Although 
these compounds are thought to be of key relevance in the inter-
actions between intestinal microbial populations and the host 
(16), their link with the lipid metabolism remains controversial. 
Our results suggest that the SCFA production paralleled the FFA 
serum levels in healthy individuals. However, this association 
was absent in the pathological framework of lupus, where an 
increased SCFA production, together with elevated FFA serum 
levels, was noted. These results are in line with those from other 
metabolic conditions [reviewed in Ref. (43)]. Additionally, our 
analyses revealed that this aberrant SCFA production can be 
linked to an altered microbial gut composition, as a reduced F/B 
ratio was related to increased SCFA fecal levels. In this scenario, 
the potential involvement of the propionate deserves a special 
mention. Propionate is mainly produced by Bacteroidetes species 
(44), thereby supporting its negative association with the F/B 
ratio observed. It is important to note that increased propionate 
fecal levels have been reported in obese individuals exhibiting 
a decreased F/B ratio (40). Furthermore, exposure of human 
intestinal organoids to propionate led to an upregulation of genes 
belonging to lipolytic pathways (45). Moreover, experimental evi-
dence from animal models and ex vivo experiments with human 
material have identified a mechanistic link between exposure to 
propionate and increased lipolysis mediated by the increased 
expression of the enzyme lipoprotein lipase (46–48). Moreover, 
a homeostatic role for propionate on glucose metabolism and 
regulation of energy intake has also been proposed. However, 
which is the actual role for propionate in human diseases required 
further elucidation. Taken together, our finding may provide a 
possible explanation for the elevated FFA serum levels in SLE, 
altered SCFA production, and overrepresentation of Bacteroidetes 
in the intestinal microbiota playing a pivotal role. The stronger 
associations of Bacteroidetes alone compared with those of the 
F/B ratio are in line with this point.
Another important result of our study was the association 
between FFA and some biomarkers of endothelial activation. 
Because of their nature, FFA are considered as common mediators 
between immunity, inflammation, and metabolism. Although 
some authors have previously proposed a role for the gut micro-
biota in the etiology of metabolic alterations and CVD (49), the 
actual players are far from being clear. Interestingly, experimental 
studies revealed a mechanistic link between propionate and leptin 
expression by human adipose and omental tissues (50), which is 
in line with our results. Nevertheless, the exact significance of this 
finding in vivo is not known. Taking into account the effects of 
FFA on inflammation, oxidative stress, and expression of adhe-
sion molecules (51–53), our results may support a role for FFA 
as a link between the (altered) gut microbiota, host metabolism, 
and disease status. It is interesting to note that differences among 
FFA in their ability to promote endothelial activation in vivo or 
in vitro have been demonstrated (54–56), which is in line with the 
associations found in our study. Importantly, these biomarkers are 
considered as early preclinical indicators of CVD development in 
the long term (57–60). Taking this into account, these associations 
may point to a very early role of the altered gut microbiota in the 
etiology of these complications. This is reinforced by the negative 
association between the intestinal dysbiosis in lupus and the levels 
of the protective IgM antibodies against phosphorylcholine (30). 
These antibodies are known to enhance apoptotic-cell clearance 
and induce anti-inflammatory pathways, explaining its negative 
association with markers of subclinical atherosclerosis (61) and 
CVD development (62) in lupus.
Finally, our approach did not identify a different FFA serum 
profile in SLE patients in comparison to HC. Although a similar 
pattern of grouping of FFA species in the PCA was observed in 
rheumatoid arthritis patients by our group (24), differences among 
FFA species between patients and controls were not observed in 
the case of lupus. Interestingly, no differences in plasma FFA pro-
filing were observed in a previous study with lupus patients (63), 
although slight alterations in the polyunsaturated fatty acids were 
reported in those with a previous history of CVD. Our results are, 
at least in part, in line with these findings, although differences in 
the experimental procedures between both studies are important. 
It is worthy to note that our group of patients was characterized 
by a low disease activity, even in the absence of glucocorticoid 
and immunosuppressive drugs. Thus, a larger study involving 
SLE patients with a higher degree of disease activity is warranted. 
However, despite no differences being found in the specific FFA 
levels, the results from the PCA emphasize the heterogeneity 
among FFA classes and suggest that FFA, despite being mostly 
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unaltered, can develop different roles under different milieu. This 
hypothesis is in line with current evidence in this field (64, 65) 
and stresses the underestimated significance of FFA as key media-
tors for the human health.
Due to the lack of direct mechanistic data in our approach, 
these results pose the question on whether the microbiota com-
position is responsible of the altered FFA levels or if, alternatively, 
increased FFA levels may lead to changes in the gut ecology. Based 
on the literature currently available, several research studies seem 
to align with the former idea. The fact that no changes in the gut 
microbiota were related to disease duration (in spite of the wide 
range of disease duration studied in the present report) is also in 
line with this idea, probably suggesting that intestinal dysbiosis 
could be present at the preclinical stages of the disease. Similarly, 
experiments of fecal transplantation in obese and lean mice also 
support the causative role of the microbiota in shaping the host 
metabolism (66). However, due to the role of FFA on inflamma-
tion, it is tempting to speculate that these molecules can prompt 
a shift toward a systemic pro-inflammatory state, which can, in 
turn, disrupt the intestinal microbiota. Experimental studies with 
mice have revealed that diet-induced obesity is accompanied by 
changes in the gut microbiota and damaged intestinal barrier 
(67, 68). Interestingly, a diet with high ω6 content resulted in 
intestinal dysbiosis in mice, the inflammatory pathways playing 
a crucial role (69). Moreover, ω3 fatty acids seem to counteract 
the effects of diet- or antibiotics-induced dysbiosis through dif-
ferent mechanisms (70, 71). Additionally, an antibacterial effect 
was observed for some FFA (72). Therefore, it is feasible that 
a bidirectional cross talk between the gut microbiota and host 
metabolism is established, with immune circuits participating in 
this interaction.
In summary, our data indicate that increased serum FFA 
levels in SLE patients may be associated with changes in the gut 
ecosystem in the framework of lupus dysbiosis. The association 
between serum FFA and SCFA supports this notion. Additionally, 
different associations between FFA species and serum biomarkers 
of endothelial activation were found, hence not only underscoring 
the heterogeneity among FFA compounds but also shedding new 
light on the gut–metabolism–CVD axis. Although the reduced 
sample size and the lack of a mechanistic data are the limitations 
of our study, to the best of our knowledge this is the first report 
supporting a connection between gut microbiota, FFA, and bio-
markers of endothelial activation. Moreover, we have provided 
a proof of concept evidence on the involvement of the intestinal 
dysbiosis in the metabolic alterations in lupus.
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